AI Article Synopsis
- Resistance to clarithromycin and levofloxacin is increasing, affecting the success of eradication treatments for patients with previous failures.
- A study of 154 patients was conducted to identify antibiotic resistance rates, risk factors, and treatment efficacy using DNA amplification techniques.
- Results showed high resistance rates (82.6% for CLA and 69.7% for LFX) and identified gastric symptoms and rural residence as significant risk factors, while susceptibility-guided treatment was more effective (75.5%) compared to empiric treatment (59.0%).
Article Abstract
Background: Resistance to clarithromycin (CLA) and levofloxacin (LFX) of is increasing in severity, and successful eradication is essential. Presently, the eradication success rate has greatly declined, leaving a large number of patients with previous treatment histories.
Aim: To investigate secondary resistance rates, explore risk factors for antibiotic resistance, and assess the efficacy of susceptibility-guided therapy.
Methods: We recruited 154 subjects positive for Urea Breath Test who attended The First Affiliated Hospital of China Medical University between July 2022 and April 2023. Participants underwent a string test after an overnight fast. The gastric juice was obtained and transferred to vials containing storage solution. Subsequently, DNA extraction and the specific DNA amplification were performed using quantitative polymerase chain reaction (qPCR). Demographic information was also analyzed as part of the study. Based on these results, the participants were administered susceptibility-guided treatment. Efficacy was compared with that of the empiric treatment group.
Results: A total of 132 individuals tested positive for the gene by qPCR technique. CLA resistance rate reached a high level of 82.6% ( = 109), LFX resistance rate was 69.7% ( = 92) and dual resistance was 62.1% ( = 82). Gastric symptoms [odds ratio (OR) = 2.782; 95% confidence interval (95%CI): 1.076-7.194; = 0.035] and rural residence (OR = 5.152; 95%CI: 1.407-18.861; = 0.013) were independent risk factors for secondary resistance to CLA and LFX, respectively. A total of 102 and 100 individuals received susceptibility-guided therapies and empiric treatment, respectively. The antibiotic susceptibility-guided treatment and empiric treatment groups achieved successful eradication rates of 75.5% (77/102) and 59.0% (59/411) by the intention-to-treat (ITT) analysis and 90.6% (77/85) and 70.2% (59/84) by the per-protocol (PP) analysis, respectively. The eradication rates of these two treatment strategies were significantly different in both ITT ( = 0.001) and PP ( = 0.012) analyses.
Conclusion: presented high secondary resistance rates to CLA and LFX. For patients with previous treatment failures, treatments should be guided by antibiotic susceptibility tests or regional antibiotic resistance profile.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10835524 | PMC |
| http://dx.doi.org/10.3748/wjg.v30.i2.184 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cost-effectiveness analysis of deep brain stimulation versus treatment as usual for treatment-resistant obsessive-compulsive disorder.
J Neurosurg
January 2025
1Department of Neurosurgery, Baylor College of Medicine, Houston, Texas.
Objective: Deep brain stimulation (DBS) is an effective neurosurgical option for patients with treatment-resistant obsessive-compulsive disorder (OCD). Despite being more costly than neuroablative procedures of comparable efficacy, DBS has gained popularity over the years for its reversibility and adjustability. Although the cost-effectiveness of DBS has been investigated extensively in movement disorders, few economic analyses of DBS for psychiatric disorders exist.
View Article and Find Full Text PDFPoint prevalence survey of antibiotic use in Mexican secondary care hospitals.
PLoS One
January 2025
National Institute of Public Health of Mexico, Center for Evaluation and Surveys Research, Cuernavaca, Morelos, Mexico.
Introduction: Tackling the inertia of growing threat of antimicrobial resistance (AMR) requires changes in how antibiotics are prescribed and utilized. The monitoring of antimicrobial prescribing in hospitals is a critical component in optimizing antibiotic use. Point prevalence surveys (PPSs) enable the surveillance of antibiotic prescribing at the patient level in small hospitals that lack the resources to establish antimicrobial stewardship programs (ASP).
View Article and Find Full Text PDFAntibiotic prescribing patterns at outpatient clinics in Western and Coastal Kenya.
PLOS Glob Public Health
January 2025
Department of Pediatrics, Division of Pediatric Infectious Diseases, Stanford University School of Medicine, Stanford, California, United States of America.
Antimicrobial resistant pathogens are a leading cause of morbidity and mortality worldwide, with overuse and misuse of antimicrobials being key contributors. We aimed to identify factors associated with antibiotic prescriptions among patients presenting to clinics in Kenya. We performed a retrospective, descriptive cohort study of persons presenting to outpatient clinics in Western and Coastal Kenya, including symptoms, physical exams, clinician assessments, laboratory results and prescriptions.
View Article and Find Full Text PDFOptimizing Pyrazinamide Use: A Low-Hanging Fruit in Improving Outcomes with Tuberculous Meningitis? Narrative Review.
Infect Dis Ther
January 2025
Christian Medical College, Vellore, Tamil Nadu, India.
Tuberculous meningitis (TBM) disables more than a third of its sufferers. Recent research has focused on optimizing the antitubercular regimen, mainly by increasing the dosage of rifampicin. However, pyrazinamide, with higher penetration into the central nervous system, is generally overlooked.
View Article and Find Full Text PDFTreatment of Seizures in People with Intellectual Disability.
CNS Drugs
January 2025
Cornwall Intellectual Disability Equitable Research (CIDER), University of Plymouth, Truro, England.
There is a synergistic relationship between epilepsy and intellectual disability (ID), and the approach to managing people with these conditions needs to be holistic. Epilepsy is the main co-morbidity associated with ID, and clinical presentation tends to be complex, associated with higher rates of treatment resistance, multi-morbidity and premature mortality. Despite this relationship, there is limited level 1 evidence to inform treatment choice for this vulnerable population.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!